Back to Search Start Over

Local Failure After Episcleral Brachytherapy for Posterior Uveal Melanoma: Patterns, Risk Factors, and Management.

Authors :
Bellerive C
Aziz HA
Bena J
Wilkinson A
Suh JH
Plesec T
Singh AD
Source :
American journal of ophthalmology [Am J Ophthalmol] 2017 May; Vol. 177, pp. 9-16. Date of Electronic Publication: 2017 Feb 03.
Publication Year :
2017

Abstract

Purpose: To evaluate the patterns, the risk factors, and the management of recurrence following brachytherapy in patients with posterior uveal melanoma, given that an understanding of the recurrence patterns can improve early recognition and management of local treatment failure in such patients.<br />Design: Retrospective cohort study.<br />Methods: Setting: Multispecialty tertiary care center.<br />Participants: A total of 375 eyes treated with episcleral brachytherapy for posterior uveal melanoma from January 2004 to December 2014. Exclusion criteria included inadequate follow-up (<1 year) and previous radiation therapy. Main Outcomes and Measures: Local control rate and time to recurrence were the primary endpoints. Kaplan-Meier estimation and Cox proportional hazards models were conducted to identify risk factors for recurrence.<br />Results: Twenty-one patients (5.6%) experienced recurrence (follow-up range 12-156 months; median 47 months). The median time to recurrence was 18 months (range 4-156 months). Five-year estimated local recurrence rate was 6.6%. The majority (90.5%) of the recurrences occurred within the first 5 years. The predominant site of recurrence was at the tumor margin (12 patients, 57.1%). Univariate analysis identified 3 statistically significant recurrence risk factors: advanced age, largest basal diameter, and the use of adjuvant transpupillary thermotherapy (TTT). Recurrent tumors were managed by repeat brachytherapy, TTT, or enucleation.<br />Conclusions: Local recurrences following brachytherapy are uncommon 5 years after episcleral brachytherapy. Follow-up intervals can be adjusted to reflect time to recurrence. Most of the eyes with recurrent tumor can be salvaged by conservative methods.<br /> (Copyright © 2017 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1879-1891
Volume :
177
Database :
MEDLINE
Journal :
American journal of ophthalmology
Publication Type :
Academic Journal
Accession number :
28163118
Full Text :
https://doi.org/10.1016/j.ajo.2017.01.024